Navigation Links
Opal Photoactivator™

ProductsOpal Photoactivator™
Company Lumenis Inc.
Item Opal Photoactivator™
Features 
  • Utilizes an advanced diode laser with consistent beam energy of 689 nanometers
  • Its modular design allows easy configuration to most diagnostic slit lamp platforms
  • Exposure time as determined by intensity, fluence, spot size, and contact lens magnification is typically only 83 seconds
  • Quality controls known as SmartLink and PowerCheck minimize the potential for inadequate drug activation
  • At-the-link power feedback, dual footswitch mode (continuous and staged), and a variable spot size of .4 to .8mm
  • Historic progress in treating AMD, pathologic myopia, and histoplasmosis
  • Only 83 seconds of low energy 689-nanometer light
  • Swift, office-based procedure
  • Only targets abnormal vessels, sparing normal vessels
  • A minimally invasive procedure
  • Received approval by FDA in April 2000
Description Until recently, most patients with age-related macular degeneration (AMD) could not expect their vision to improve or stabilize with or without treatment. Now, the Opal Photoactivator laser from Lumenis has revolutionized the standard of care and offers patients renewed hope.

Lumenis designed the Opal Photoactivator especially for use in photodynamic therapy with verteporfin, a drug produced by CIBA Vision Corporation, the eye care unit of Novartis AG. The Opal laser used in conjunction with Visudyne therapy represents an incredible advance in ocular photodynamic therapy (PDT). In this approach, the Opal laser is used not as a cutting tool but to activate a therapeutic drug in the patient's eye, providing a minimally invasive, focused treatment for AMD.

The Opal offers innovative features unavailable on any other laser -- features that ensure uncompromised treatment, safety, and patient care.

Info Lumenis Inc.
Customer Service: 877-lumenis
Web site: http://www.lumenis.com

Related medicine products :

1. Adson Cranial Rongeur
2. Bacon Cranial Rongeur
3. Instatrak - Cranial
4. Neuroclip Cranial Flap Fixation System
5. TEW Cranial/Spinal Retractor (A 1090)
6. De Vilbiss Cranial Rongeur
7. Stookey Cranial Rongeur
8. Marchac Cranial Rongeur
9. Cranial Drill
10. Hudson Cranial Drill
11. Tew Cranial/Spinal Retractor
... The Zeus Scientific, Inc. ... for the qualitative and quantitative ... human serum by the indirect ... assay can determine or confirm ...
Measles IgM Enzyme-Linked Immunosorbent Assay (ELISA) is intended for the in vitro determination of Measles IgM antibodies in human serum. For in vitro diagnostic use. High complexity test....
Measles IgM ELISA test is an enzyme linked immunosorbent assay (ELISA) for the detection of IgG class antibodies to Measles (Rubeola) in human serum or plasma....
... For over 30 years, Digisonics has ... workstations with the first review station, ... management, and the best multi-modality reporting., ... performance image review workstations, professional reporting ...
Medicine Products:
(Date:2/24/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has published a ... an astounding statement when he says that the entire Bible was written for the ... times so plainly that anyone should be able to see the time period. He ...
(Date:2/24/2017)... Emeryville, CA (PRWEB) , ... February 24, 2017 ... ... Esparza for qualifying into the Senior International Elite division on February 12th. ... All Around divisions at the elite qualifier competition held in Las Vegas, Nevada. ...
(Date:2/23/2017)... ... 23, 2017 , ... The Lymphoma Research Foundation (LRF) – ... serving the lymphoma community through a comprehensive series of education programs, outreach initiatives ... Miami Beach to host its Swirl: Miami Wine Tasting Event on March 28, ...
(Date:2/23/2017)... ... 23, 2017 , ... Rosica Communications, a national PR ... media management, corporate communications, SEO and cause marketing, is opening an office in ... Hampshire, Massachusetts and Canada, Rosica will focus on expanding its footprint. , ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... uncertainty in clinical trials, today announced that Premier Research, a leading clinical development ... , Clinical trials are becoming increasingly complex, due in part to an array ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... , Südkorea, 23. Februar 2017 LG Innotek ... Sterilisationsaufgaben vorgestellt. Die Sterilisationsleistung beträgt das 1,5-fache des 45-mW-Moduls ... Strahlung im Bereich zwischen 200 und 280 nm und eignet ... Bakterien, indem es ihre DNA zerstört. Das Produkt von ... ...
(Date:2/23/2017)... , Feb. 23, 2017 ITL Limited, ( ASX: ... excellent results for the half year ended 31 December 2016 compared ... Growth Update" presentation can be viewed here . ... (Dec 2015: $1.04m; up 104%) Earnings per share ... Revenue of $17.5m (Dec 2015: $15.7m; up 11%) ...
(Date:2/23/2017)... -- Research and Markets has announced the addition of the ... their offering. ... research Menopause Drugs Price Analysis and Strategies - 2016, provides drug pricing ... the following questions: What are the key ... in the Global Menopause market? What are the unit ...
Breaking Medicine Technology: